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Abstract
Background: Evidence-based diabetes guidelines generally neglect comorbidity, which may interfere with diabetes
management. The prevalence of comorbidity described in patients with type 2 diabetes (T2D) shows a wide range
depending on the population selected and the comorbid diseases studied. This exploratory study aimed to
establish comorbidity rates in an unselected primary-care population of patients with T2D.
Methods: This was a cohort study of 714 adult patients with newly diagnosed T2D within the study period (1985-
2007) in a practice-based research network in the Netherlands. The main outcome measures were prevalence and
incidence density rates of chronic comorbid diseases and disease clusters. All chronic disease episodes registered in
the practice-based research network were considered as comorbidities. We categorised comorbidity into
‘concordant’ (that is, shared aetiology, risk factors, and management plans with diabetes) and ‘discordant’
comorbidity. Prevalence and incidence density were assessed for both categories of comorbidity.
Results: The mean observation period was 17.3 years. At the time of diabetes diagnosis, 84.6% of the patients had
one or more chronic comorbid disease of ‘any type’, 70.6% had one or more discordant comorbid disease, and
48.6% and 27.2% had three or more chronic comorbid diseases of ‘any type’ or of ‘discordant only’, respectively.
A quarter of those without any comorbid disease at the time of their diabetes diagnosis developed at least one
comorbid disease in the first year afterwards. Cardiovascular diseases (considered concordant comorbidity) were
the most common, but there were also high rates of musculoskeletal and mental disease. Discordant comorbid
diseases outnumbered concordant diseases.
Conclusions: We found high prevalence and incidence density rates for both concordant and discordant
comorbidity. The latter may interfere with diabetes management, thus future research and clinical practice should
take discordant comorbidity in patients with T2D into account.
Keywords: type 2 diabetes, comorbidity, primary care, prevalence, incidence
Background
Ageing of the population contributes to the increasing
prevalence of diabetes [1-4] and of multimorbidity, that is,
the co-occurrence of multiple diseases within one person
[5]. The prevalence of multimorbidity is estimated at 16 to
58% in adults in primary care or population-based settings
[6-9]. Diabetes mellitus (type 2 diabetes; T2D) is a chronic
disease with marked effects on mortality and healthcare
expenditure [2], and its prevalence in the USA was esti-
mated at 8% in 2010 [10].
When referring to a specific disease such as diabetes as
an index condition, any co-occurring conditions are con-
sidered comorbidity [5,11]. In primary care, over 40% of
patients with diabetes also have comorbidity [12], which is
as high as 70 to 95% in selected diabetes cohorts [13,14].
Diabetes treatment may provide lower benefit to patients
with diabetes and comorbidity [15,16]. Comorbidity has a
negative effect on the quality of life of patients with dia-
betes [17-20], and substantially increases their healthcare* Correspondence: h.luijks@elg.umcn.nl
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utilization [12,14]. It also negatively influences their self-
management and emotional well-being [21].
The number of studies on comorbidity in T2D is lim-
ited. Previous studies focused mainly on ‘concordant’
comorbidity, that is, conditions that share pathogenesis,
risk factors, and/or management plans with T2D (for
instance, hypertension) [22]. ‘Discordant’ combinations
[22], that is, diseases without shared pathogenesis, risk fac-
tors, or management, remain largely unexplored. Diabetes
patients with concordant and discordant comorbidity
show similarly increased healthcare utilization [12].
Recommendations for clinical approaches to comorbidity
in general and of discordant combinations in particular
are rarely provided in evidence-based (diabetes) guidelines
[23].
Epidemiologic descriptions of both concordant and dis-
cordant comorbidity in an unselected T2D population
may increase understanding of the heterogeneity of
populations with T2D, and may encourage consideration
of co-existing discordant comorbid conditions in current
T2D management. To date, epidemiological research on
comorbidity in T2D has been limited to prevalence esti-
mates from cross-sectional studies only. The frequency
and sequence in which comorbid diseases occur may
have important implications for aetiology, prognosis, and
management [11]. Consequently, it would be useful to
assess the prevalence and the incidence of comorbid dis-
eases in patients with T2D.
The aims of this study were to establish the prevalence
and types of an extensive range of chronic comorbid dis-
eases in patients with T2D at the time of their diabetes
diagnosis, and to establish the incidence density of new
chronic comorbid diseases in these patients over time. We
limited neither the number nor the types of chronic
comorbid diseases to be studied in advance.
Methods
Design, setting, and patients
We performed a cohort study in a population of 714
patients with newly diagnosed T2D (patient demo-
graphics are shown in Table 1), using morbidity data
from all patients with newly diagnosed T2D from the
Continuous Morbidity Registration (CMR), a practice-
based research network in the Nijmegen region located
in the eastern part of the Netherlands. In the Nether-
lands, all patients are listed with a general practitioner
(GP) and receive professional healthcare through this GP.
The CMR consists of four general practices, in which the
GPs have been recording prospectively all episodes of
morbidity for all enlisted patients from 1967 onwards,
including diagnoses made by specialists after referral
[24]. Diagnoses recorded in the CMR have been shown
to have high validity [25,26]. In general, longitudinal data
collected in research networks such as the CMR are
representative of primary care [27]. The CMR contains
each patient’s date of birth, gender and socioeconomic
status (SES), based on the Dutch Standard Classification
of Occupations [28], classified as low, moderate, or high
[29]. For many years, the total population in these prac-
tices had been relatively stable, at around 12,000 patients,
with approximately 80% being adults. From 1998
onwards, the population increased steadily, reaching
14,000 in 2006 [30]. Data from the CMR are representa-
tive for distribution of age, gender, and SES in the Neth-
erlands [30,31].
Studies based on CMR data comply with the Code of
Conduct for Health Research, which has been approved
by the Data Protection Authorities for conformity with
the applicable Dutch privacy legislation. For this study,
Table 1 Characteristics of the 714 patients included in
the study
Variables
Sex, n (%)
Male 351 (49.2)
Female 363 (50.8)
SES,1 n (%)
Low 362 (50.7)
Middle 282 (39.5)
High 62 (8.7)
Missing 8 (1.1)
Age at diabetes diagnosis, years, mean (± SD,
range)
Total 63.2 (± 12.8, 21 to 95)
2
Males 61.9 (± 12.8, 21 to 94)
Females 64.4 (± 12.7, 23 to 95)
Time after diabetes,3 years, mean (± SD) 6.2 (± 4.7)2
Males 5.9 (± 4.5)
Females 6.6 (± 4.9)
Time before diabetes,4 years, mean (± SD) 11.1 (± 6.3)
Time in study population, years, mean (± SD) 17.3 (± 6.0)
Year of diagnosis,5 , n (%)
1985-1989 100 (14.0)
1990-1999 276 (38.7)
2000-2006 338 (47.3)
Reason for follow-up ending, n (%)
End of study period 462 (64.7)
Deceased 155 (21.7)
Moved/left practice 97 (13.6)
1SES, socioeconomic status.
2Significant difference for males and females (P < 0.05). Non-significant
gender differences not shown.
3Observation time in the study population after diabetes diagnosis.
4Observation time in the study population before diabetes diagnosis.
5Year of diagnosis of diabetes, classified into categories corresponding to the
latest issues of the Dutch College of General Practitioner’s T2D guideline. The
first, second and third issues were published in 1989, 1999, and 2006
respectively.
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approval of an external ethics committee was not
required.
This explorative study period covered the years 1985 to
2007. During this period, the CMR’s morbidity classifica-
tion system was not changed, which enabled us to com-
pare identical diagnoses consistently over time. Our study
population had a dynamic composition, that is, observa-
tion period from start to end points varied between
patients. The observation time for individual patients
began with the start of the study period (1 January 1985),
including for patients who had already been registered in
the CMR database before 1985, or the date of a patient’s
enrolment as a patient in the CMR, whichever occurred
first. The observation period for patients terminated either
at the end of our study period (31 December 2006), or
with a patient’s death or deregistration from the practice,
whichever occurred first. We included all adult patients
(aged 18 years or over) with T2D. The diabetes diagnosis
had to be made within the study period (that is, incident
cases) in accordance with universally accepted criteria
[32], and was verified in the patient’s medical record when
the age at the time of diagnosis was less than 45 years.
Diabetes care in the CMR practices has been shown to
achieve outcomes comparable with those reported under
randomized controlled trial conditions [33].
Comorbidity
We considered all chronic diseases as comorbidities,
regardless of whether they occurred before or after the
patient’s diabetes diagnosis. The CMR distinguishes
approximately 500 diagnostic codes (the ‘E-list codes’).
The GPs label each code as a new or ongoing episode for
a known disease. No generally accepted definition of
‘chronicity’ exists, but frequently used criteria for chroni-
city include duration, pattern with recurrence or dete-
rioration, and consequences on a patient’s life measured
by various outcomes [34]. For the current study, we
defined chronic conditions as diseases (a) that are persis-
tent (duration of 6 months or longer); (b) from which the
patient does not recover; and (c) that require healthcare
attention. Those conditions that did not evidently fulfil
all three criteria were presented to a panel of eight
experienced GPs from the CMR practices, who cate-
gorised each condition as chronic, non-chronic or condi-
tionally chronic. We distinguished ‘conditionally chronic’
diseases as those that can but do not need to have a
chronic course, depending on the individual; examples
are depression, asthma, and epilepsy. In these cases, the
ongoing episodes at patient level defined the presence or
absence of chronicity for this individual. When the expert
panel unanimously judged a specific disease as chronic,
we considered this particular disease as chronic in further
analyses. In cases of disagreement between the panel
members, the disease was labeled as conditionally
chronic. In these cases, ongoing episodes at the patient
level defined individual chronicity. All chronic diseases
were regarded as cases of comorbidity of T2D. The final
list contained 67 chronic and 63 conditionally chronic
disorders (see Additional file 1).
Finally, comorbid diseases were classified into clusters,
in accordance with the following chapters of The Inter-
national Classification of Primary Care (ICPC)-1: cardi-
ovascular, musculoskeletal, mental, eye, ear, urology,
male and female genital system, respiratory, skin, diges-
tive, endocrine and metabolic, neurologic, blood(-form-
ing organs) and lymphatics, and general and unspecified
diseases [35]. We also distinguished the subcomponents
of infectious diseases and neoplasms (malignancies) as
separate clusters. Small and mutually related clusters
were combined into one category (see Additional file 2
for the cluster arrangement).
Using T2D as the index disease, we considered all
chronic diseases from the cardiovascular cluster as con-
cordant and all other diseases as discordant comorbidity.
Statistical analysis
We calculated the prevalence of chronic comorbidity at
the date of diabetes diagnosis as the number of patients
with a specified (cluster of) chronic comorbidity, divided
by the total number of patients, and expressed it as a pro-
portion, with 95% confidence interval (CI). A cluster was
present if at least one of the chronic diseases within this
cluster had been diagnosed in an individual patient.
We also calculated the incidence density rate of
chronic comorbidity for the first year before diabetes
diagnosis, and for the first year, the first 5 years, and the
first 10 years after diabetes diagnosis. We divided the
number of new cases of (a cluster of) chronic comorbid
diseases within the specified time period by the number
of person-years at risk for a diagnosis of that particular
comorbidity, and expressed the incidence density rate as
the number of new cases per 1,000 patient-years at risk
(with 95% CI). Patients who had already developed the
particular comorbid disease before the specified period
were no longer considered to be at risk, because a
chronic disease can be diagnosed only once, and persists
subsequently. For incident cases of chronic comorbidity,
only the time until diagnosis of this comorbid disease
contributed to the number of patient-years.
To analyse the overall burden of comorbidity in our
study population, we counted the total number of comor-
bid chronic diseases and clusters at the time of diabetes
diagnosis, and calculated the mean and standard devia-
tion. We also calculated the prevalence and the incidence
density for having ‘any’ chronic comorbidity and for hav-
ing three or more chronic comorbid diseases or clusters.
We tested patient characteristics for gender differences
with the independent t-test for continuous variables and
Luijks et al. BMC Medicine 2012, 10:128
http://www.biomedcentral.com/1741-7015/10/128
Page 3 of 10
the c2 tests for categorical variables. In all cases, signifi-
cance was set at P ≤ 0.05. SPSS software (version 18.0;
SPSS Inc., Chicago, IL, USA) supported the analyses.
Results
Patient characteristics
The mean ± SD age at diabetes diagnosis was 63.2 ± 12.8
years, and the mean observation time was 17.3 ± 6.0 years.
Generally, patients had a longer period before than after
diabetes diagnosis within our study period. Patient age
showed a normal distribution, whereas time before/after
diabetes did not, with over-representation of extreme
values (maximum observation time within study period).
Women were generally older than men at the time of their
diabetes diagnosis and had a longer follow-up, but the
total observation time did not differ between women and
men. Table 1 shows the patient characteristics; values are
shown by gender only for those characteristics with signifi-
cant gender differences.
Prevalence of chronic comorbidity at time of diabetes
diagnosis
We assessed the prevalence of chronic comorbidity at
the time of diabetes diagnosis (Table 2, Table 3). Only
15.4% of the patients did not have chronic comorbidity.
Counting discordant diseases only (that is, excluding
cardiovascular disease; CVD) showed that 70.6% (95%
CI 67.2 to 73.9%) had at least one discordant comorbid
disease in addition to T2D.
Having three or more chronic comorbid diseases when
T2D was diagnosed was not uncommon: approximately
half (48.6%; 95% CI 44.9 to 52.3) of the population had
at least one chronic comorbid disease, and approxi-
mately a quarter (27.2%; 95% CI 24.0 to 30.5) had three
or more discordant chronic comorbid diseases. From
the prevalence data of diseases from different clusters
(Table 3), it follows that this was often a heterogeneous
mix of diseases.
CVDs were the most prevalent comorbid diseases at
the time of diabetes diagnosis: 64.0% (95% CI 60.4 to
67.5) (Table 4). Musculoskeletal and mental diseases
were also very common. There was a high prevalence of
chronic functional somatic symptoms [36] and deafness
as single diseases. Table 5 shows data on the most com-
mon chronic comorbid diseases from every cluster.
Prevalent chronic psychosis, obsessive compulsive disor-
der, phobia, schizophrenia, dementia, mental retardation,
or Down’s syndrome were combined as a heterogeneous
group of chronic diseases affecting patients’ mental states,
which were found to affect 3.8% of the total population at
time of diabetes diagnosis.
Chronic comorbidity before diabetes diagnosis
The incidence density rate of any chronic comorbidity
(both concordant and discordant) in the year before dia-
betes diagnosis was very high (Table 3). In general,
comorbid disease clusters with high prevalence rates at
diabetes diagnosis also had high incidence density rates
in the year before diabetes diagnosis (Table 4). For some
diseases and clusters, the incidence density rate in the
year before diabetes was particularly high compared with
the prevalence rate at this time, and also with the inci-
dence density rate after diabetes diagnosis. Examples are
CVD (especially myocardial infarction) and male urogen-
ital diseases (Table 4, Table 5).
Chronic comorbidity after diabetes diagnosis
In the years after diabetes diagnosis, the incidence density
rate of chronic comorbidity remained high. A quarter of
those without any chronic comorbid disease at the time of
diabetes diagnosis developed at least one comorbid disease
in the first subsequent year (263.7 new cases per 1,000
patient-years at risk, 95% CI 160.3 to 367.0) (Table 3).
Eye and ear diseases (cataract in particular) had a high
incidence density rate after diabetes diagnosis as compared
with the year before diagnosis, and also compared with the
prevalence rate at diabetes diagnosis: 46.9 per 1,000
patient-years at risk during the first year. Skin diseases and
respiratory and endocrine diseases had a lower incidence
density rate after diabetes diagnosis than before. The inci-
dence density rate of mental diseases was particularly low
in the first year after diabetes diagnosis, with no new cases
of chronic depression the first year after diabetes diagnosis
(Table 4, Table 5).
Discussion
Principal findings
In this study, we established the prevalence and incidence
of comorbidity in patients with T2D. We found that
84.6% of the patients with newly diagnosed T2D in a pri-
mary-care population had at least one chronic comorbid
disease at the time of their diagnosis, and both concor-
dant and discordant comorbidity were common. Inci-
dence density rates after diabetes diagnosis showed that
rates of chronic comorbidity further increased after
Table 2 Mean ± SD number of (clusters of) chronic
comorbid diseases at date of diabetes diagnosis1,2
Single chronic diseases Clusters of comorbidity3
All Discordant only4 All Discordant only4
Number 2.9 ± 2.4 1.7 ± 1.7 2.1 ± 1.5 1.5 ± 1.3
1This table describes the mean of chronic comorbid diseases present in our
total population (n = 714) at the date of diagnosis of type 2 diabetes.
2Data are displayed both for the total count of single comorbid diseases and
for the number of clusters of chronic comorbid diseases. We also
distinguished ‘any type’ of comorbid diseases and ‘discordant diseases only’.
3Clusters: comorbid diseases were classified into clusters, following The
International Classification of Primary Care (ICPC)-1 chapters.
4Discordant: without shared pathogenesis, risk factors, or management.
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diabetes onset. This study clearly showed the heterogene-
ity of this primary-care population with T2D in terms of
comorbidity.
Relation to other studies
The prevalence of comorbidity in patients with T2D in
this study was similar to [14,37] or higher than [12,13]
those of previous studies. The number of comorbid dis-
eases considered in a study contributes to any prevalence
estimate [7,38], and our work had the largest number.
The relatively high prevalence of comorbidity we found is
more pronounced when one considers that we investi-
gated a primary-care population including all adult T2D
patients, as opposed to studies that included only patients
over 65 years of age [14,37] or those requiring inpatient
diabetes treatment [13]. Patients with discordant comor-
bidity outnumbered those with concordant comorbidity,
a finding similar to earlier CMR-based research on
comorbidity in patients with heart failure as the index
disease [39]. Diabetes is not necessarily causally related
to additional diseases, but co-existing chronic diseases
may interfere with diabetes management in several ways
[14-20]. These results encourage us to reflect on the gen-
eral lack of attention to (discordant) comorbidity in evi-
dence-based diabetes guidelines [23].
Patients with comorbidity may prioritize one condition
over another, and experience overwhelming effects of an
individual disease [21,40]. A recent study showed that phy-
sician-experienced complexity of patients with diabetes
increased with prevalent discordant comorbidity, but not
with concordant comorbidity, implying that improvement
in diabetes management could be made merely by focus-
ing on patient-centred rather than disease-specific inter-
ventions [41]. Patient-centred management is exactly what
GPs prioritize in the management of multimorbidity [42];
however, the current tendency is to incentivise disease-
specific instead of holistic care, thereby counteracting
patient-centred approaches [43-46]. The extent of chronic
comorbidity in patients with T2D, as shown in the current
study, urges an approach of complementing disease-speci-
fic strategies with a personalized, generalist approach for
the management of patients with multimorbidity [6,42].
Table 4 Prevalence and incidence density of clusters of chronic comorbidity; before, at time of, and after diabetes
diagnosis (DD)1
Before diabetes Date of DD After diabetes
Disease cluster2 ID year before
DD3
Prevalence at DD, % (95%
CI)4
ID first year after
DD3
ID first 5 years after
DD3
ID first 10 years after
DD3
Cardiovascular 176.9 (127.9 to
225.9)
64.0 (60.4 to 67.5) 122.3 (77.0 to 167.6) 105.5 (82.9 to 128.0) 101.0 (82.1 to 119.9)
Musculoskeletal 31.3 (15.5 to 47.1) 31.1 (27.8 to 34.6) 21.6 (8.2 to 35.0) 27.9 (20.1 to 35.8) 31.6 (24.6 to 38.6)
Mental 15.2 (4.7 to 25.8) 24.1 (21.1 to 27.3) 5.8 (0.0 to 12.4) 10.4 (5.9 to 14.8) 12.6 (8.5 to 16.7)
Eye and ear 29.6 (15.1 to 44.0) 22.7 (19.7 to 25.9) 46.9 (28.1 to 65.6) 45.3 (35.7 to 54.9) 42.8 (34.9 to 50.7)
Urogenital (male and
female)
23.7 (11.3 to 36.1) 15.4 (12.9 to 18.2) 17.6 (6.7 to 28.5) 16.9 (11.5 to 22.4) 15.5 (11.2 to 19.8)
Urogenital5 26.7 (8.2 to 45.2) 13.4 (10.1 to 17.3) 14.1 (0.3 to 27.9) 12.8 (6.1 to 19.5) 14.1 (8.2 to 20.0)
Urogenital6 20.6 (4.1 to 37.0) 17.4 (13.7 to 21.5) 21.0 (4.2 to 37.8) 21.0 (12.4 to 29.6) 16.9 (10.5 to 23.2)
Respiratory 6.8 (0.1 to 13.4) 14.1 (11.7 to 16.9) 3.4 (0.0 to 8.2) 4.3 (1.6 to 6.9) 3.8 (1.7 to 5.8)
Skin 8.0 (1.0 to 15.1) 9.9 (7.9 to 12.3) 1.6 (0.0 to 4.8) 3.8 (1.3 to 6.3) 3.1 (1.3 to 5.0)
Digestive 3.2 (0.0 to 7.5) 8.5 (6.7 to 10.8) 3.2 (0.0 to 7.7) 3.7 (1.3 to 6.1) 4.0 (1.9 to 6.1)
Endocrine and metabolic 9.4 (1.9 to 17.0) 8.4 (6.5 to 10.6) 4.8 (0.0 to 10.3) 6.7 (3.4 to 9.9) 5.7 (3.2 to 8.2)
Malignancies 14.0 (4.8 to 23.1) 7.3 (5.5 to 9.4) 14.4 (5.0 to 23.7) 15.9 (10.9 to 20.9) 17.5 (13.2 to 21.9)
Neurologic 1.5 (0.0 to 4.4) 3.4 (2.2 to 4.9) 1.5 (0.0 to 4.5) 2.0 (0.2 to 3.7) 1.9 (0.5 to 3.3)
Blood and lymphatics 4.4 (0.0 to 9.3) 0.4 (0.1 to 1.1) 0.0 1.5 (0.0 to 3.0) 1.6 (0.3 to 2.8)
Infectious 0.0 0.3 (0.0 to 0.9) 0.0 0.0 0.0
Abbreviations: ID, incidence density.
1Confidence intervals (CIs) for proportions were calculated with the Mid-P exact test. CIs for person time were calculated as normal approximation to the Poisson
interval. Values smaller than 0.05 have been truncated to 0.0.
2Clusters: comorbid diseases were classified into clusters, after The International Classification of Primary Care (ICPC)-1 chapters. Sorted by decreasing prevalence
at date of DD. The cluster ‘general/unspecified’ was removed because it contained only one case.
3Incidence density in a specified time period was calculated as the number of new cases of one or more diseases within a cluster of comorbidity, divided by the
number of person-years at risk for a diagnosis of the particular cluster. Expressed as number of new cases per 1,000 patient-years at risk (95% CI).
4Prevalence at diabetes date was calculated as the number of patients with comorbidity in the cluster of interest at date of DD, divided by the total number of
patients (n = 714).
5Prevalence and incidence density displayed only for men in the study population.
6Prevalence and incidence density displayed only for women in the study population.
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Table 5 Prevalence and incidence density of chronic comorbid diseases: before, at time of, and after diabetes
diagnosis (DD)1
Chronic disease2 Before
diabetes
Date of DD After diabetes
ID,3 year
before DD
Prevalence4 at DD, %
(95% CI)
ID3,first year
after DD
ID3,first 5 years
after DD
ID3, first 10 years
after DD
Hypertension 75.2 (49.9 to
100.5)
38.4 (34.9 to 42.0) 56.8 (33.6 to 80.0) 42.6 (32.1 to 53.0) 40.0 (31.5 to 48.5)
Varicose veins; venous insufficiency 16.5 (5.7 to 27.3) 21.4 (18.5 to 24.6) 13.3 (3.5 to 23.2) 12.5 (7.6 to 17.4) 10.8 (7.0 to 14.6)
Angina pectoris 13.1 (4.0 to 22.2) 12.3 (10.1 to 14.9) 13.6 (4.2 to 22.9) 14.4 (9.5 to 19.3) 15.1 (10.9 to 19.3)
Atrial fibrillation/flutter 18.9 (8.2 to 29.7) 8.7 (6.8 to 10.9) 8.1 (1.0 to 15.2) 11.2 (7.0 to 15.5) 12.3 (8.6 to 16.0)
Myocardial infarction 17.2 (7.0 to 27.3) 8.5 (6.7 to 10.8) 4.8 (0.0 to 10.3) 7.8 (4.3 to 11.3) 9.6 (6.4 to 12.8)
(Congestive) heart failure 15.6 (5.9 to 25.3) 8.0 (6.2 to 10.2) 16.1 (6.1 to 26.1) 12.7 (8.3 to 17.2) 16.2 (12.0 to 20.4)
CVA 15.1 (5.7 to 24.5) 4.9 (3.5 to 6.7) 12.5 (3.8 to 21.1) 11.2 (7.1 to 15.4) 14.7 (10.7 to 18.6)
Intermittent claudication 9.0 (1.8 to 16.2) 4.3 (3.0 to 6.0) 4.6 (0.0 to 9.9) 4.3 (1.8 to 6.9) 3.5 (1.6 to 5.4)
TIA 8.9 (1.8 to 16.0) 2.9 (1.9 to 4.4) 4.6 (0.0 to 9.8) 5.5 (2.6 to 8.3) 5.9 (3.4 to 8.4)
Heart valve disease 6.0 (0.1 to 11.8) 2.9 (1.9 to 4.4) 7.6 (0.9 to 14.3) 5.8 (2.9 to 8.7) 5.6 (3.2 to 8.0)
Osteoarthritis, knee 14.7 (5.1 to 24.3) 12.0 (9.8 to 14.6) 6.7 (0.1 to 13.3) 13.9 (9.1 to 18.8) 13.3 (9.4 to 17.2)
Osteoarthritis, hip 7.9 (1.0 to 14.9) 8.7 (6.8 to 10.9) 1.6 (0.0 to 4.8) 3.7 (1.3 to 6.1) 5.4 (3.0 to 7.8)
Osteoarthritis, other 7.9 (1.0 to 14.8) 8.4 (6.5 to 10.6) 9.7 (1.9 to 17.5) 8.4 (4.7 to 12.0) 8.1 (5.1 to 11.1)
Osteoarthritis, cervical spine 6.2 (0.1 to 12.3) 7.1 (5.4 to 9.2) 4.8 (0.0 to 10.2) 2.4 (0.5 to 4.4) 2.5 (0.9 to 4.1)
Lumbar osteoarthritis 4.7 (0.0 to 9.9) 7.0 (5.3 to 9.1) 8.0 (1.0 to 14.9) 5.3 (2.4 to 8.2) 4.5 (2.3 to 6.8)
Rheumatoid arthritis; ankylosing
spondylarthritis
0.0 1.4 (0.7 to 2.5) 0.0 0.4 (0.0 to 1.1) 1.0 (0.0 to 2.1)
(Chronic) functional somatic
symptoms
5.4 (0.0 to 11.5) 19.2 (16.4 to 22.2) 3.7 (0.0 to 8.8) 3.8 (1.2 to 6.4) 3.5 (1.4 to 5.6)
Depression 3.0 (0.0 to 7.1) 2.5 (1.5 to 3.9) 0.0 1.2 (0.0 to 2.5) 1.3 (0.2 to 2.5)
Alzheimer’s disease 7.3 (0.9 to 13.8) 1.5 (0.8 to 2.7) 3.0 (0.0 to 7.2) 5.0 (2.3 to 7.7) 7.1 (4.4 to 9.8)
Mental retardation 0.0 1.5 (0.8 to 2.7) 0.0 0.0 0.0
Deafness 16.6 (6.3 to 26.9) 13.6 (11.2 to 16.3) 13.7 (4.2 to 23.2) 15.5 (10.3 to 20.6) 13.7 (9.7 to 17.7)
Cataract 17.1 (7.0 to 27.2) 7.8 (6.0 to 10.0) 42.8 (26.3 to 59.2) 34.0 (26.4 to 41.6) 33.6 (27.2 to 40.0)
Glaucoma 3.0 (0.0 to 7.1) 2.9 (1.9 to 4.4) 3.0 (0.0 to 7.3) 3.1 (1.0 to 5.3) 2.4 (0.8 to 4.0)
Urinary incontinence5 13.1 (0.3 to 26.0) 13.2 (10.0 to 17.0) 16.6 (2.1 to 31.2) 17.3 (9.7 to 24.8) 14.7 (8.9 to 20.4)
Prostatic hyperplasia/hypertrophy6 19.3 (3.9 to 34.8) 9.7 (6.9 to 13.1) 3.4 (0.0 to 10.0) 8.7 (3.3 to 14.1) 10.4 (5.5 to 15.4)
Uterine fibroid5 0.0 2.2 (1.0 to 4.1) 0.0 0.7 (0.0 to 2.2) 0.5 (0.0 to 1.7)
Urinary incontinence6 9.0 (0.0 to 19.1) 2.0 (0.9 to 3.9) 9.4 (0.0 to 19.9) 5.7 (1.5 to 9.9) 5.1 (1.8 to 8.4)
COPD 3.3 (0.0 to 7.8) 11.2 (9.0 to 13.7) 1.7 (0.0 to 4.9) 3.7 (1.3 to 6.2) 3.4 (1.5 to 5.3)
Asthma 3.0 (0.0 to 7.1) 3.1 (2.0 to 4.6) 3.0 (0.0 to 7.3) 1.2 (0.0 to 2.5) 0.8 (0.0 to 1.7)
Psoriasis 4.6 (0.0 to 9.8) 5.6 (4.1 to 7.5) 1.6 (0.0 to 4.6) 2.0 (0.2 to 3.7) 1.6 (0.0 to 1.7)
Diaphragmatic hernia 1.5 (0.0 to 4.4) 2.5 (1.5 to 3.9) 0.0 0.0 0.3 (0.0 to 0.8)
Colonic diverticula; diverticulitis 1.5 (0.0 to 4.4) 2.0 (1.1 to 3.2) 3.0 (0.0 to 7.2) 2.3 (0.5 to 4.2) 2.1 (0.6 to 3.6)
Gout 4.5 (0.0 to 9.7) 4.1 (2.8 to 5.7) 0.0 3.5 (1.2 to 5.9) 3.0 (1.2 to 4.7)
Hypothyroidism 4.4 (0.0 to 9.5) 2.5 (1.5 to 3.9) 1.5 (0.0 to 4.5) 1.6 (0.0 to 3.1) 1.6 (0.3 to 2.9)
Hyperthyroidism 0.0 2.2 (1.3 to 3.5) 3.0 (0.0 to 7.2) 1.2 (0.0 to 2.5) 0.8 (0.0 to 1.7)
Breast cancer5 2.9 (0.0 to 8.7) 2.8 (1.4 to 4.9) 8.9 (0.0 to 18.9) 7.5 (2.8 to 12.1) 7.1 (3.4 to 10.9)
Prostate cancer6 0.0 1.7 (0.7 to 3.5) 6.2 (0.0 to 14.8) 2.4 (0.0 to 5.1) 3.9 (1.0 to 6.8)
Endometrial cancer5 0.0 1.4 (0.5 to 3.0) 2.9 (0.0 to 8.6) 0.7 (0.0 to 2.2) 0.5 (0.0 to 1.5)
Skin cancer 2.9 (0.0 to 7.0) 0.7 (0.3 to 1.5) 0.0 1.1 (0.0 to 2.4) 1.8 (0.5 to 3.2)
Colon cancer 0.0 0.6 (0.2 to 1.3) 0.0 1.5 (0.0 to 3.0) 2.1 (0.6 to 3.5)
Lung/bronchial cancer 1.5 (0.0 to 4.3) 0.3 (0.0 to 0.9) 3.0 (0.0 to 7.1) 1.5 (0.0 to 3.0) 1.8 (0.5 to 3.1)
Luijks et al. BMC Medicine 2012, 10:128
http://www.biomedcentral.com/1741-7015/10/128
Page 7 of 10
Strengths and limitations of the study
To our knowledge, this study is the first to describe the
development of chronic comorbidity over time in
patients with T2D. We were able to identify comorbidity
diagnosed before diabetes diagnosis. Selection of patients
with a diagnosis of T2D and all comorbidity data were
based on the most reliable source, that is, physician diag-
noses, rather than patient self-report [17,37] or extraction
of medication prescriptions [47].
Diabetes in this study served as an example of a com-
mon chronic disease with standardized management
plans. The objectives of this exploratory study were to
establish the prevalence rates of a range of chronic
comorbid conditions and their development over time.
Given the nature of the CMR database, comparing
comorbidity data in our diabetes population with a con-
trol group with another index disease, such as osteoar-
thritis, would have been possible. However, this would
have distracted from the intended epidemiologic descrip-
tion of chronic comorbidity in T2D patients. This study
did not aim to quantify the comorbidity rate in patients
with T2D compared with patients with other chronic dis-
eases, or to compare the rates within specific subgroups
of patients with T2D or at different time periods within
the study. Considering the large number of comorbid
conditions and clusters studied, such comparisons would
have resulted in numerous statistically significant differ-
ences or interactions of uncertain clinical relevance.
Instead, the current epidemiologic description may lead
to more detailed exploration of specific conditions or
subgroups for future research.
The particular strengths of the study are that the dia-
betes population we studied was unselected, and that we
did not restrict comorbidity only to prevalent or concor-
dant chronic diseases. Our data reflect the total burden of
chronic comorbidity in patients with T2D in general.
Currently, no universally accepted definition of ‘chronic
diseases’ is available. Within any definition, personaliza-
tion of the concept of chronicity to the individual patient
level is preferred, although often not attained [34,48]. An
Australian primary-care code set applied the same cri-
teria for chronicity as we did [34]. However, by adding
the distinction of conditional chronicity based on physi-
cian-assigned ongoing episodes, we were able to persona-
lize chronicity in our analyses. For diseases from which
patients may recover (for example, depression), or for
diseases with either episodic or chronic courses (for
example, asthma, gout), we consider our classification
comes closer to the correct description of chronicity than
would a list with invariable chronic diseases.
Comments on specific comorbid diseases
Concordant comorbidity (that is, CVDs) showed the
highest prevalence and incidence density rates. Although
this cluster contained a large number of diseases, the
main explanation for the high rate is the concordance
with T2D. Care-related factors will have added to this
finding. For instance, a GP will be more attentive for
T2D in a patient who has had a myocardial infarction.
The suggestion that presence of a disease enhances atten-
tion for other diseases [49,50] might be particularly the
case for concordant combinations.
For discordant combinations also, care-dependent fac-
tors might contribute to the high rates of comorbidity.
There was an evidently increased incidence of cataract in
the year after diabetes diagnosis. The reason for this may
be that screening for diabetic retinopathy resulted in ear-
lier diagnosis of, or otherwise unobserved cataract diag-
noses. Moreover, people might not raise certain issues
until they visit their doctor for other health problems;
such restraints can contribute to a higher incidence of
conditions such as incontinence in the first years after
diabetes diagnosis. These examples illustrate that despite
the high rate of comorbidity reported, our results may
still be an underestimation, as the comorbidity data refer
to disease episodes truly experienced by patients and pre-
sented to their GP.
Musculoskeletal diseases have an antagonistic effect
on physical exercise, which is part of the recommended
treatment for diabetes [11]. Around 30% (3/10) patients
Table 5 Prevalence and incidence density of chronic comorbid diseases: before, at time of, and after diabetes diagno-
sis (DD)1 (Continued)
Migraine 0.0 2.0 (1.1 to 3.2) 1.5 (0.0 to 4.5) 0.8 (0.0 to 1.8) 1.1 (0.0 to 2.1)
Abbreviations: DD, date of diabetes diagnosis; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; ID, incidence density; TIA, transient
ischemic attack.
1Confidence intervals for proportions were calculated with the Mid-P exact test. Confidence intervals for person time were calculated as a normal approximation
to the Poisson interval. Values smaller than 0.0 have been truncated to 0.0.
2Diseases sorted by cluster, in decreasing prevalence at the date of DD diabetes date, and within the particular cluster by decreasing prevalence at date of DD.
3Incidence density in a specified time period was calculated as the number of new cases of comorbidity, divided by the number of person-years at risk for a
diagnosis of the particular comorbidity. Expressed as number of new cases per 1,000 patient-years at risk (95% CI).
4Prevalence at diabetes date was calculated as the number of patients with the comorbidity of interest at the date of DD, divided by the total number of
patients (n = 714).
5Prevalence and incidence displayed only for women in the study population.
6Prevalence and incidence displayed only for men in the study population.
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with T2D had musculoskeletal disease at time of dia-
betes diagnosis, and of those unaffected, an additional
32 new cases per 1,000 patient-years at risk followed
during the next 10 years. These are substantial figures,
which are higher than chronic musculoskeletal diseases
in the overall CMR population [30], and these cases are
likely to interfere with diabetes management.
Diabetes treatment focuses on prevention of complica-
tions [51]. The presence of a malignancy may overshadow
the importance of co-existing diabetes, and thus treatment
priorities may alter. Dutch researchers found that patients
with diabetes who had cancer received less aggressive can-
cer treatment than those without diabetes [52].
Parallel to the reluctance of GPs to prescribe interven-
tions for depression in patients with comorbidity [53],
Dutch GPs might be conservative in ‘adding’ a chronic
mental disease diagnosis after a diagnosis of diabetes.
Including less prevalent diseases in our study enabled us
to localize a heterogeneous group of patients with
chronic comorbidity who possibly have difficulties in
self-managing their diabetes. One in 25 patients had
chronic psychosis, obsessive compulsive disorder, pho-
bia, schizophrenia, dementia, mental retardation, or
Down’s syndrome when diagnosed with diabetes. A
‘standard’ approach to diabetes would often not respond
to these patients’ abilities or needs.
Conclusions
This study illustrated the complexity of the T2D popula-
tion under GP care, in terms of chronic comorbidity.
We have shown that the ‘straightforward’ patient with
T2D without (discordant) comorbidity is relatively rare.
Management of diabetes demands management of
comorbidity, including discordant diseases. Clinical
guidelines have an important role in diabetes manage-
ment, but their external validity may be questioned by
taking comorbidity into consideration [23,43,44]. A
patient-centred approach can be of added value in the
management of patients with diabetes with chronic
comorbidity.
In conclusion, this study provides new knowledge on
the epidemiology of chronic comorbidity in T2D. We
hope it will inform ongoing research in this area, and is
taken into account in diabetes management.
Additional material
Additional file 1: Comorbidity.
Additional file 2: Clusters of comorbidity.
Abbreviations
CMR: Continuous Morbidity Registration; CVD: cardiovascular disease; GP:
general practitioner; T2D: type 2 diabetes.
Acknowledgements
We would like to thank all GPs and practice assistants in the CMR practices
in Lent, Nijmegen, Oosterhout and Doesburg for longitudinal morbidity
recording.
Authors’ contributions
HL, TS, and MB developed the concept of the study and its design, with
contributions from WdG, HB, TLJ, and CvW. Acquisition of data was
performed by HL and HB, and drafting of the manuscript by HL and TS. The
statistical analyses were performed by HL, HB, TS, and MB. HB, CvW, TLJ, MB,
and WdG critically revised the manuscript for important intellectual content.
WdG, CvW and TLJ supervised the study. All authors have read and
approved the manuscript for publication. The corresponding author had full
access to all the data in the study, and takes responsibility for the integrity
of the data and the accuracy of the data analysis.
Authors’ information
HL is a GP resident and PhD candidate; TS is a senior researcher; HB is a
senior researcher and statistician; CvW is a GP and professor of primary care;
TLJ is a GP and professor of primary care; MB is a senior researcher and
epidemiologist; WdG is a GP and senior researcher.
Competing interests
No competing interests are reported. HL has received a research grant from
SBOH, Foundation for Family Medicine Residency Training in the
Netherlands. There was no specific funding for the presented work.
Received: 13 June 2012 Accepted: 29 October 2012
Published: 29 October 2012
References
1. Zimmet P, Alberti KG, Shaw J: Global and societal implications of the
diabetes epidemic. Nature 2001, 414:782-787.
2. Van Dieren S, Beulens JW, Van der Schouw YT, Grobbee DE, Neal B: The
global burden of diabetes and its complications: an emerging
pandemic. Eur J Cardiovasc Prev Rehabil 2010, 17:S3-8.
3. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ: Impact of
recent increase in incidence on future diabetes burden: U.S., 2005-2050.
Diabetes Care 2006, 29:2114-2116.
4. King H, Aubert RE, Herman WH: Global burden of diabetes, 1995-2025:
prevalence, numerical estimates, and projections. Diabetes Care 1998,
21:1414-1431.
5. Van den Akker M, Buntinx F, Knottnerus J: Comorbidity or multimorbidity:
what’s in a name? A review of literature. Eur J Gen Pract 1996, 2:65-70.
6. Barnett K, Mercer SW, Norbury M, Watt G, Wyke S, Guthrie B: Epidemiology
of multimorbidity and implications for health care, research, and
medical education: a cross-sectional study. Lancet 2012, 380:37-43.
7. Salisbury C, Johnson L, Purdy S, Valderas JM, Montgomery AA:
Epidemiology and impact of multimorbidity in primary care: a
retrospective cohort study. Br J Gen Pract 2011, 61:e12-21.
8. Van Oostrom SH, Picavet HS, Van Gelder BM, Lemmens LC, Hoeymans N,
Verheij RA, Schellevis FG, Baan CA: [Multimorbidity and comorbidity in the
Dutch population–data from general practices]. Ned Tijdschr Geneeskd
2011, 155:A3193.
9. Taylor AW, Price K, Gill TK, Adams R, Pilkington R, Carrangis N, Shi Z,
Wilson D: Multimorbidity - not just an older person’s issue. Results from
an Australian biomedical study. BMC Public Health 2010, 10:718.
10. National diabetes fact sheet: national estimates and general information
on diabetes and prediabetes in the United States, 2011. .
11. Valderas JM, Starfield B, Sibbald B, Salisbury C, Roland M: Defining
comorbidity: implications for understanding health and health services.
Ann Fam Med 2009, 7:357-363.
12. Struijs JN, Baan CA, Schellevis FG, Westert GP, Van den Bos GA:
Comorbidity in patients with diabetes mellitus: impact on medical
health care utilization. BMC Health Serv Res 2006, 6:84.
13. Ashton CM, Septimus J, Petersen NJ, Souchek J, Menke TJ, Collins TC,
Wray NP: Healthcare use by veterans treated for diabetes mellitus in the
Veterans Affairs medical care system. Am J Manag Care 2003, 9:145-150.
14. Niefeld MR, Braunstein JB, Wu AW, Saudek CD, Weller WE, Anderson GF:
Preventable hospitalization among elderly Medicare beneficiaries with
type 2 diabetes. Diabetes Care 2003, 26:1344-1349.
Luijks et al. BMC Medicine 2012, 10:128
http://www.biomedcentral.com/1741-7015/10/128
Page 9 of 10
15. Greenfield S, Billimek J, Pellegrini F, Franciosi M, De BG, Nicolucci A,
Kaplan SH: Comorbidity affects the relationship between glycemic
control and cardiovascular outcomes in diabetes: a cohort study. Ann
Intern Med 2009, 151:854-860.
16. Huang ES, Zhang Q, Gandra N, Chin MH, Meltzer DO: The effect of
comorbid illness and functional status on the expected benefits of
intensive glucose control in older patients with type 2 diabetes: a
decision analysis. Ann Intern Med 2008, 149:11-19.
17. Maddigan SL, Feeny DH, Majumdar SR, Farris KB, Johnson JA:
Understanding the determinants of health for people with type 2
diabetes. AmJPublic Health 2006, 96:1649-1655.
18. Talley NJ, Young L, Bytzer P, Hammer J, Leemon M, Jones M, Horowitz M:
Impact of chronic gastrointestinal symptoms in diabetes mellitus on
health-related quality of life. Am J Gastroenterol 2001, 96:71-76.
19. Wändell PE: Quality of life of patients with diabetes mellitus. An
overview of research in primary health care in the Nordic countries.
Scand J Prim Health Care 2005, 23:68-74.
20. De Grauw WJ, Van de Lisdonk EH, Behr RR, Van Gerwen WH, Van den
Hoogen HJ, Van Weel C: The impact of type 2 diabetes mellitus on daily
functioning. Fam Pract 1999, 16:133-139.
21. Beverly EA, Wray LA, Chiu CJ, Weinger K: Perceived challenges and
priorities in co-morbidity management of older patients with Type 2
diabetes. Diabet Med 2011, 28:781-784.
22. Piette JD, Kerr EA: The impact of comorbid chronic conditions on
diabetes care. Diabetes Care 2006, 29:725-731.
23. Lugtenberg M, Burgers JS, Clancy C, Westert GP, Schneider EC: Current
guidelines have limited applicability to patients with comorbid
conditions: a systematic analysis of evidence-based guidelines. PLoS One
2011, 6:e25987.
24. Van Weel C: The Continuous Morbidity Registration Nijmegen:
background and history of a Dutch general practice database. Eur J Gen
Pract 2008, 14(Suppl 1):5-12.
25. Van Weel C: Validating long term morbidity recording. J Epidemiol
Community Health 1995, 49(Suppl 1):29-32.
26. Van Weel-Baumgarten EM, Van den Bosch WJ, Van den Hoogen HJ,
Zitman FG: The validity of the diagnosis of depression in general
practice: is using criteria for diagnosis as a routine the answer? Br J Gen
Pract 2000, 50:284-287.
27. Van Weel C: Longitudinal research and data collection in primary care.
Ann Fam Med 2005, 3:S46-51.
28. Statistics Netherlands, 2012. [http://www.cbs.nl/en-GB/default.htm].
29. Schers H, Bor H, van den Hoogen H, van Weel C: What went and what
came? Morbidity trends in general practice from the Netherlands. Eur J
Gen Pract 2008, 14(Suppl 1):13-24.
30. Van de Lisdonk EH, Van den Bosch WJHM, Lagro-Janssen ALM, Schers HJ:
[Diseases in general practice]. Maarssen: Elsevier gezondheidszorg;, 5 2008.
31. Statistics Netherlands, 2012. [http://statline.cbs.nl].
32. De Grauw WJ, Van den Hoogen HJ, Van de Lisdonk EH, Van Gerwen WH,
Van Weel C: Control group characteristics and study outcomes: empirical
data from a study on mortality of patients with type 2 diabetes mellitus
in Dutch general practice. J Epidemiol Community Health 1998, 52(Suppl
1):9S-12S.
33. De Grauw WJ, Van Gerwen WH, Van de Lisdonk EH, Van den Hoogen HJ,
Van den Bosch WJ, Van Weel C: Outcomes of audit-enhanced monitoring
of patients with type 2 diabetes. J Fam Pract 2002, 51:459-464.
34. O’Halloran J, Miller GC, Britt H: Defining chronic conditions for primary
care with ICPC-2. Fam Pract 2004, 21:381-386.
35. Bentsen BG: International classification of primary care. Scand J Prim
Health Care 1986, 4:43-50.
36. Olde Hartman TC, Lucassen PL, Van de Lisdonk EH, Bor HH, Van Weel C:
Chronic functional somatic symptoms: a single syndrome? Br J Gen Pract
2004, 54:922-927.
37. Caughey GE, Ramsay EN, Vitry AI, Gilbert AL, Luszcz MA, Ryan P,
Roughead EE: Comorbid chronic diseases, discordant impact on mortality
in older people: a 14-year longitudinal population study. J Epidemiol
Community Health 2010, 64:1036-1042.
38. Schram MT, Frijters D, Van de Lisdonk EH, Ploemacher J, De Craen AJ, De
Waal MW, Van Rooij FJ, Heeringa J, Hofman A, Deeg DJ, Schellevis FG:
Setting and registry characteristics affect the prevalence and nature of
multimorbidity in the elderly. J Clin Epidemiol 2008, 61:1104-1112.
39. Van der Wel MC, Jansen RW, Bakx JC, Bor HH, Olderikkert MG, Van Weel C:
Non-cardiovascular co-morbidity in elderly patients with heart failure
outnumbers cardiovascular co-morbidity. Eur J Heart Fail 2007, 9:709-715.
40. Bayliss EA, Steiner JF, Fernald DH, Crane LA, Main DS: Descriptions of
barriers to self-care by persons with comorbid chronic diseases. Ann
Fam Med 2003, 1:15-21.
41. Grant RW, Wexler DJ, Ashburner JM, Hong CS, Atlas SJ: Characteristics of
“complex” patients with type 2 diabetes mellitus according to their
primary care physicians. Arch Intern Med 2012, 172:821-823.
42. Luijks HD, Loeffen MJ, Lagro-Janssen AL, van Weel C, Lucassen PL,
Schermer TR: GPs’ considerations in multimorbidity management: a
qualitative study. Br J Gen Pract 2012, 62:503-510.
43. Tinetti ME, Bogardus ST Jr, Agostini JV: Potential pitfalls of disease-specific
guidelines for patients with multiple conditions. N Engl J Med 2004,
351:2870-2874.
44. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW: Clinical practice
guidelines and quality of care for older patients with multiple comorbid
diseases: implications for pay for performance. JAMA 2005, 294:716-724.
45. Roland M: Linking physicians’ pay to the quality of care–a major
experiment in the United kingdom. N Engl J Med 2004, 351:1448-1454.
46. May C, Montori VM, Mair FS: We need minimally disruptive medicine. BMJ
2009, 339:b2803.
47. Caughey GE, Roughead EE, Vitry AI, McDermott RA, Shakib S, Gilbert AL:
Comorbidity in the elderly with diabetes: Identification of areas of
potential treatment conflicts. Diabetes Res Clin Pract 2010, 87:385-393.
48. Perrin EC, Newacheck P, Pless IB, Drotar D, Gortmaker SL, Leventhal J,
Perrin JM, Stein RE, Walker DK, Weitzman M: Issues involved in the
definition and classification of chronic health conditions. Pediatrics 1993,
91:787-793.
49. Bayliss EA, Blatchford PJ, Newcomer SR, Steiner JF, Fairclough DL: The
effect of incident cancer, depression and pulmonary disease
exacerbations on type 2 diabetes control. J Gen Intern Med 2011,
26:575-581.
50. Min LC, Wenger NS, Fung C, Chang JT, Ganz DA, Higashi T, Kamberg CJ,
MacLean CH, Roth CP, Solomon DH, Young RT, Reuben DB: Multimorbidity
is associated with better quality of care among vulnerable elders. Med
Care 2007, 45:480-488.
51. Standards of medical care in diabetes–2009. Diabetes Care 2009,
32(Suppl 1):S13-61.
52. Van de Poll-Franse LV, Houterman S, Janssen-Heijnen ML, Dercksen MW,
Coebergh JW, Haak HR: Less aggressive treatment and worse overall
survival in cancer patients with diabetes: a large population based
analysis. Int J Cancer 2007, 120:1986-1992.
53. Kendrick T, Dowrick C, McBride A, Howe A, Clarke P, Maisey S, Moore M,
Smith PW: Management of depression in UK general practice in relation
to scores on depression severity questionnaires: analysis of medical
record data. BMJ 2009, 338:b750.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1741-7015/10/128/prepub
doi:10.1186/1741-7015-10-128
Cite this article as: Luijks et al.: Prevalence and incidence density rates
of chronic comorbidity in type 2 diabetes patients: an exploratory
cohort study. BMC Medicine 2012 10:128.
Luijks et al. BMC Medicine 2012, 10:128
http://www.biomedcentral.com/1741-7015/10/128
Page 10 of 10
